JP2017523141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523141A5 JP2017523141A5 JP2016572482A JP2016572482A JP2017523141A5 JP 2017523141 A5 JP2017523141 A5 JP 2017523141A5 JP 2016572482 A JP2016572482 A JP 2016572482A JP 2016572482 A JP2016572482 A JP 2016572482A JP 2017523141 A5 JP2017523141 A5 JP 2017523141A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- symptoms
- optionally substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*(C*(C)C(NO)=O)C(Nc(cc1)ccc1N(C(N1Cc2ccccc2)=O)SC1=O)=O Chemical compound C*(C*(C)C(NO)=O)C(Nc(cc1)ccc1N(C(N1Cc2ccccc2)=O)SC1=O)=O 0.000 description 1
- MZHOEBYFTUIMTG-UHFFFAOYSA-N COc1ccc(Cc2nnc(-c(cc3)ccc3C(NO)=O)[o]2)cc1 Chemical compound COc1ccc(Cc2nnc(-c(cc3)ccc3C(NO)=O)[o]2)cc1 MZHOEBYFTUIMTG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011413P | 2014-06-12 | 2014-06-12 | |
| US62/011,413 | 2014-06-12 | ||
| PCT/US2015/035659 WO2015192078A1 (en) | 2014-06-12 | 2015-06-12 | Compositions and methods for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023904A Division JP7015856B2 (ja) | 2014-06-12 | 2020-02-17 | がん治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523141A JP2017523141A (ja) | 2017-08-17 |
| JP2017523141A5 true JP2017523141A5 (enExample) | 2018-07-26 |
| JP6663863B2 JP6663863B2 (ja) | 2020-03-13 |
Family
ID=54834452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572482A Active JP6663863B2 (ja) | 2014-06-12 | 2015-06-12 | がん治療のための組成物及び方法 |
| JP2020023904A Active JP7015856B2 (ja) | 2014-06-12 | 2020-02-17 | がん治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023904A Active JP7015856B2 (ja) | 2014-06-12 | 2020-02-17 | がん治療のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10029997B2 (enExample) |
| EP (2) | EP3154544B1 (enExample) |
| JP (2) | JP6663863B2 (enExample) |
| KR (1) | KR102567244B1 (enExample) |
| CN (1) | CN106794175B (enExample) |
| AU (3) | AU2015274334B2 (enExample) |
| CA (1) | CA2950774C (enExample) |
| ES (1) | ES2960601T3 (enExample) |
| MX (1) | MX388409B (enExample) |
| WO (1) | WO2015192078A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388409B (es) | 2014-06-12 | 2025-03-19 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| CN115175673A (zh) * | 2020-02-26 | 2022-10-11 | 上海科技大学 | 双硫仑在抗冠状病毒中的应用 |
| CN111658766A (zh) * | 2020-07-06 | 2020-09-15 | 陈长宏 | GSK3β及其激动剂在上皮源性恶性肿瘤治疗与康复中的应用 |
| WO2024019667A1 (en) * | 2022-07-21 | 2024-01-25 | Agency For Science, Technology And Research | Method of inhibiting epithelial-mesenchymal transition and cancer metastasis |
| CN115197167B (zh) * | 2022-07-22 | 2023-07-28 | 中国药科大学 | 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 |
| WO2025240627A1 (en) * | 2024-05-14 | 2025-11-20 | Cedars-Sinai Medical Center | Methods and compositions for treating pancreatic cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711492A (en) * | 1970-12-08 | 1973-01-16 | Basf Ag | Thiadiazolidinediones |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| WO1998027069A1 (en) * | 1996-12-17 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of mmp or tnf |
| US6045925A (en) | 1997-08-05 | 2000-04-04 | Kansas State University Research Foundation | Encapsulated nanometer magnetic particles |
| EP1165500A1 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| YU85403A (sh) * | 2001-05-11 | 2006-03-03 | Pharmacia Corporation | Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora |
| EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| US6676729B2 (en) | 2002-01-02 | 2004-01-13 | International Business Machines Corporation | Metal salt reduction to form alloy nanoparticles |
| EP1339075A1 (en) | 2002-02-25 | 2003-08-27 | Motorola, Inc. | Magnetic nanomaterials and synthesis method |
| US6878445B2 (en) | 2002-03-08 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Nanoparticle coated material and production method of same |
| EP1551842A1 (en) | 2002-10-15 | 2005-07-13 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| DE10331439B3 (de) | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
| EP1622615A4 (en) * | 2003-05-13 | 2009-02-18 | Smithkline Beecham Corp | INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE |
| GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
| TW593158B (en) | 2003-07-31 | 2004-06-21 | Ind Tech Res Inst | Magnetic nanoparticle |
| US7396589B2 (en) | 2003-07-31 | 2008-07-08 | Industrial Technology Research Institute | Core-shell magnetic nanoparticles comprising an inner-transition element |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| GB0402496D0 (en) * | 2004-02-04 | 2004-03-10 | Argenta Discovery Ltd | Novel compounds |
| EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| GB0418328D0 (en) | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| US7700193B2 (en) | 2005-04-08 | 2010-04-20 | Industrial Technology Research Institute | Core-shell structure with magnetic, thermal, and optical characteristics and manufacturing method thereof |
| US20070264199A1 (en) | 2005-09-26 | 2007-11-15 | Labhasetwar Vinod D | Magnetic nanoparticle composition and methods for using the same |
| EP1976976A4 (en) * | 2005-12-23 | 2010-12-15 | Univ Rochester | TREATMENT OF NEURO-AIDS USING INHIBITORS OF GLYCODY SYNTHASE KINASE (GSK) -3 |
| US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| EP2043633B1 (en) * | 2006-07-18 | 2016-07-06 | University of Rochester | Thiadiazolidinone derivatives for treating cancer |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| TWI519508B (zh) * | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
| EP2231147A2 (en) * | 2007-12-13 | 2010-09-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| US20120015942A1 (en) * | 2010-07-19 | 2012-01-19 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| EA201490228A1 (ru) * | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| JP6073377B2 (ja) * | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーＡｓｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｐａｒｔｎｅｒｓ Ｌｌｃ | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
| JP5722264B2 (ja) | 2012-03-23 | 2015-05-20 | 株式会社日立ハイテクノロジーズ | データ処理装置、データ容量増加抑制方法 |
| IN2015DN03235A (enExample) * | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
| CN103848795B (zh) * | 2014-03-07 | 2016-08-17 | 山东大学 | 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
| MX388409B (es) | 2014-06-12 | 2025-03-19 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
-
2015
- 2015-06-12 MX MX2016016507A patent/MX388409B/es unknown
- 2015-06-12 US US15/317,559 patent/US10029997B2/en active Active
- 2015-06-12 AU AU2015274334A patent/AU2015274334B2/en active Active
- 2015-06-12 JP JP2016572482A patent/JP6663863B2/ja active Active
- 2015-06-12 EP EP15806839.5A patent/EP3154544B1/en active Active
- 2015-06-12 CN CN201580042796.XA patent/CN106794175B/zh active Active
- 2015-06-12 KR KR1020177000702A patent/KR102567244B1/ko active Active
- 2015-06-12 EP EP23188783.7A patent/EP4306173A3/en active Pending
- 2015-06-12 CA CA2950774A patent/CA2950774C/en active Active
- 2015-06-12 WO PCT/US2015/035659 patent/WO2015192078A1/en not_active Ceased
- 2015-06-12 ES ES15806839T patent/ES2960601T3/es active Active
-
2018
- 2018-06-19 US US16/012,536 patent/US10266505B2/en active Active
-
2019
- 2019-03-04 US US16/292,011 patent/US10836735B2/en active Active
-
2020
- 2020-02-17 JP JP2020023904A patent/JP7015856B2/ja active Active
- 2020-10-08 US US17/066,397 patent/US20210276964A1/en not_active Abandoned
-
2021
- 2021-03-17 AU AU2021201667A patent/AU2021201667B2/en active Active
-
2023
- 2023-02-16 AU AU2023200895A patent/AU2023200895A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523141A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2019510832A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2018504379A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2010539095A5 (enExample) | ||
| JP2017506666A5 (enExample) | ||
| JP2015500884A5 (enExample) | ||
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
| JP2010511721A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2014508753A5 (enExample) | ||
| JP2011526917A5 (enExample) | ||
| JP2013520443A5 (enExample) |